Morgan Stanley Daxor Corp Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Daxor Corp stock. As of the latest transaction made, Morgan Stanley holds 1 shares of DXR stock, worth $9. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Holding current value

% of portfolio

0.0%

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$7.86 - $9.7 $7 - $9	1 New	1 $0
Q1 2024 Oct 17, 2024	BUY	$7.19 - $10.03 $1,258 - $1,755	175 New	175 $1,000
Q4 2023 Aug 16, 2024	BUY	$7.26 - $9.6 $1,270 - $1,680	175 New	175 $1,000
Q3 2021 Nov 15, 2021	BUY	$8.77 - $12.05 $1,534 - $2,108	175 New	175 $2,000

Others Institutions Holding DXR

# of Institutions

Shares Held

87.3K

Call Options Held

Put Options Held

Vanguard Group Inc Valley Forge, PA

48.8K
Shares

$440,428
0.0% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

14.8K
Shares

$133,685
0.0% of portfolio
Keyes, Stange & Wooten Wealth Management, LLC Palm Coast, FL

14.6K
Shares

$131,800
0.07% of portfolio
Advisor Group Holdings, Inc. Phoenix, AZ

7.2K
Shares

$64,944
0.0% of portfolio
Ubs Group Ag

1.24K
Shares

$11,148
0.0% of portfolio

View Full List

About DAXOR CORP

Ticker DXR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 4,041,670
Market Cap $36.5M
Description
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used i...

More about DXR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account